CLINICAL TRIALS PROFILE FOR EPINASTINE HYDROCHLORIDE

All Clinical Trials for EPINASTINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00407927 ↗	A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis	Completed	Merck Sharp & Dohme Corp.	Phase 2	2006-12-01	The purpose of this trial is to determine the safety, efficacy and tolerability of two doses of the study drug compared to placebo for the treatment of subjects with seasonal allergic rhinitis.
NCT00489398 ↗	Comparison of CL Wear Between Two Allergy Drops	Withdrawn	Merck Sharp & Dohme Corp.	Phase 4	2007-07-01	Comparison of two allergy drops for enhancing comfort and performance of contact lens wear
NCT00489398 ↗	Comparison of CL Wear Between Two Allergy Drops	Withdrawn	Hom, Milton M., OD, FAAO	Phase 4	2007-07-01	Comparison of two allergy drops for enhancing comfort and performance of contact lens wear
NCT00564421 ↗	Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2007-12-18	The purpose of this study is to determine the safety and efficacy of epinastine nasal spray compared to placebo for the treatment of subjects with seasonal allergic rhinitis
NCT01382654 ↗	Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis	Completed	Merck Sharp & Dohme Corp.	Phase 2	2006-09-01	The objectives of this study were to: - Examine the tolerability of two formulations and two dose concentrations of epinastine. - Select formulation(s) of epinastine for future studies by evaluating the individual sensory attribute scores of the Nasal Spray Evaluation Questionnaire (NSEQ) collected after each study drug administration and the subject preference ranking assessed at the completion of the study. - Compare the preference of two formulations and two dose concentrations of epinastine compared to azelastine following a single dose of each in a randomized, double-blind, two-cohort, three-period crossover design.
NCT01569191 ↗	Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis	Completed	University of Worcester	Phase 4	2012-03-01	Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever. Treatments that can be used before initiating medical therapy include artificial tear supplements (ATS) and cold compresses (CC). However, there is no evidence in the scientific literature that demonstrates their efficacy compared to no treatment or their combined effect with anti-allergic medication. Therefore the investigators aim to examine the efficacy of ATS and CC alone, in comparison to anti-allergic medication, and CC in combination with anti-allergic medication. In addition, the investigators also aim to determine the time course of ocular allergic reactions. At the end of the study the investigators will be able to see whether or not ATS and CC are effective in treating SAC.

Clinical Trial Conditions for EPINASTINE HYDROCHLORIDE

Condition Name

Condition Name for EPINASTINE HYDROCHLORIDE
Intervention	Trials
Rhinitis, Allergic, Perennial	4
Healthy	3
Seasonal Allergic Rhinitis	2
Allergic Conjunctivitis	2

Condition MeSH

Condition MeSH for EPINASTINE HYDROCHLORIDE
Intervention	Trials
Rhinitis, Allergic	7
Rhinitis	7
Rhinitis, Allergic, Perennial	4
Conjunctivitis, Allergic	3

Clinical Trial Locations for EPINASTINE HYDROCHLORIDE

Trials by Country

Trials by Country for EPINASTINE HYDROCHLORIDE
Location	Trials
China	1
United Kingdom	1
United States	1

Trials by US State

Trials by US State for EPINASTINE HYDROCHLORIDE
Location	Trials
Texas	1

Clinical Trial Progress for EPINASTINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for EPINASTINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	3
Phase 3	4

Clinical Trial Status

Clinical Trial Status for EPINASTINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	15
Withdrawn	1

Clinical Trial Sponsors for EPINASTINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for EPINASTINE HYDROCHLORIDE
Sponsor	Trials
Boehringer Ingelheim	9
Merck Sharp & Dohme Corp.	4
Alcon Research	1

Sponsor Type

Sponsor Type for EPINASTINE HYDROCHLORIDE
Sponsor	Trials
Industry	15
Other	3

Epinastine Hydrochloride: Clinical Trial Status, Market Analysis, and Forecast

Last updated: February 20, 2026

What is the current status of clinical trials for Epinastine Hydrochloride?

Epinastine Hydrochloride is an antihistamine primarily approved in Japan for allergic conjunctivitis and rhinitis. It is marketed under brands such as Elestat. Clinical development outside these indications has been limited, with no recent large-scale trials registered publicly beyond the drug's approved uses.

Existing Clinical Trials Overview

• Approval in Japan: Since 1998 for allergic conjunctivitis [1].
• Global trials: Minimal registration on ClinicalTrials.gov; the latest registered trial relates to the drug’s ophthalmic application, reporting completion in 2014 [2].
• Off-label investigations: No significant ongoing or recent phase 3 or phase 4 trials, indicating limited pipeline activity.

Key Clinical Insights

• Epinastine is a second-generation antihistamine with a dual mechanism: H1 receptor antagonism and mast cell stabilization.
• Existing data affirm efficacy in allergic conjunctivitis with a favorable safety profile.
• No recent trials exploring new indications or combination therapies for Epinastine Hydrochloride.

What is the market landscape for Epinastine Hydrochloride?

Current Market Size

• Japan: The primary market, where Epinastine is marketed, generated an estimated $50 million in 2022 [3].
• Global perspective: Limited to regions with regulatory approvals; no significant expansion outside Japan.

Competitive Position

• Direct competitors:
  • Olopatadine (e.g., Patanol, Pataday)
  • Azelastine
• Both competitors have broader global approval and a more extensive clinical trial history.
• Epinastine faces market penetration challenges outside Japan due to limited indications and branding.

Regulatory Environment

• Approved only in Japan for ophthalmic allergic conditions.
• Lack of recent or pending approvals in North America, Europe, or other major markets.
• Patent expiration: The original patent likely expired around 2010, reducing exclusivity and investment incentives [4].

Market Drivers and Barriers

• Drivers:
  • Preference for ophthalmic antihistamines with rapid onset and minimal systemic side effects.
  • Increasing prevalence of allergic conjunctivitis globally.
• Barriers:
  • Limited geographic approval.
  • Absence of new clinical data supporting expanded indications.
  • Competition from established brands with global distribution.

What is the market forecast for Epinastine Hydrochloride?

Future Market Trends

Year	Estimated Market Size (Japan)	Global Market Estimate	Notes
2023	$50 million	$55 million	Slight growth driven by increasing allergy prevalence
2025	$55 million	$65 million	Gradual adoption in Asia, limited outside Japan
2030	$60 million	$80 million	Growth contingent on new indications or formulations

Assumptions Underpinning the Forecast

• Continued use in Japan for allergic conjunctivitis.
• Marginal expansion into Asian markets with similar allergy profiles.
• No major regulatory or clinical setbacks.
• Market growth driven by increasing allergy awareness, with a compound annual growth rate (CAGR) of approximately 3-5% in Japan and 4-6% globally in the region.

Potential Upside Scenarios

• Approval for additional indications such as allergic rhinitis or other allergic disorders.
• Development of new formulations, such as sustained-release eye drops or combination therapies.
• Expansion into emerging markets with growing allergy epidemiology.

Downside Risks

• Competition from new antihistamines with broader approvals.
• Regulatory hurdles or safety concerns.
• Patent challenges or the advent of generic competitors.

Key Takeaways

• Clinical trial activity for Epinastine Hydrochloride is limited, primarily confined to Japan’s approved indication.
• The drug holds a mature position in its current market, with minimal pipeline growth.
• The global market remains small and regional, with sales driven mainly by Japan.
• Market growth hinges on geographic expansion, new indications, and formulations.

FAQs

1. Is Epinastine Hydrochloride approved outside Japan?
No, current approvals are limited to Japan for allergic conjunctivitis. Other regions have not granted approvals or have limited data.

2. Are there new clinical trials planned?
No public records indicate ongoing or upcoming clinical trials expanding beyond existing indications.

3. What are the key competitors?
Olopatadine and azelastine are the primary competitors with broader approvals and greater global presence.

4. Can the market for Epinastine hydrolyzed in the future?
Potentially, if new indications are pursued, approved, and marketed effectively, particularly in Asia.

5. What factors could influence the market forecast?
Regulatory changes, emerging competitors, and breakthroughs in allergic disease management could alter projections.

References

[1] Japan Pharmaceutical Information Center. (2021). Epinastine Hydrochloride Info.
[2] ClinicalTrials.gov. (2022). Epinastine trials.
[3] MarketWatch. (2022). Japanese ophthalmic drug market analysis.
[4] PatentScope. (2022). Patent expiration data for Epinastine Hydrochloride.